SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Stock Information for Surface Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Surface Oncology Inc.

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.